Share on StockTwits

Research analysts at Piper Jaffray cut their target price on shares of LipoScience (NASDAQ:LPDX) from $3.80 to $3.25 in a report released on Wednesday. The firm currently has a “neutral” rating on the stock. Piper Jaffray’s price objective indicates a potential upside of 8.70% from the company’s current price.

LipoScience (NASDAQ:LPDX) opened at 2.99 on Wednesday. LipoScience has a 52 week low of $2.92 and a 52 week high of $5.59. The stock’s 50-day moving average is $3.24 and its 200-day moving average is $3.50. The company’s market cap is $45.6 million.

LipoScience (NASDAQ:LPDX) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.03. Analysts expect that LipoScience will post $-0.82 EPS for the current fiscal year.

LipoScience, Inc is a vitro diagnostic company. The Company’s diagnostic test, the nuclear magnetic resonance (NASDAQ:LPDX) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.